Resistia creates microbiota‑derived biopolymers and immunostimulants that break down bacterial biofilms, restoring the effectiveness of existing antibiotics. By degrading the protective matrix and boosting host immunity, its platform enables higher cure rates for biofilm‑associated infections such as prosthetic joint infections and chronic wounds, targeting WHO‑priority pathogens.
Funding
Funding not disclosed
Founders
Product
Problem
Antibiotic treatments often fail against bacterial biofilms, which can make bacteria up to 1,000 times more resistant and block drug penetration, leading to chronic infections and increased mortality worldwide.
Solution
Resistia develops microbiota‑derived biopolymers and immunostimulants that disrupt biofilm structures, restoring the susceptibility of bacteria to conventional antibiotics. By breaking the protective matrix, the platform enables standard antibiotics to reach their targets and achieve higher cure rates. The approach combines biofilm eradication with synergistic immune activation, enhancing the efficacy of existing drugs without requiring new antibiotic classes. Resistia applies this dual‑action technology across a pipeline targeting WHO‑priority pathogens in both medical‑device‑associated and chronic wound indications.
Target Audience
Primary customers are pharmaceutical and medical‑device companies developing treatments for prosthetic joint infections, diabetic foot ulcers, chronic wounds, and other biofilm‑associated infections.
Features
- Microbiota‑derived biopolymers that physically degrade biofilm matrices, increasing antibiotic penetration
- Immunostimulant components that boost host immune response to cleared infections
- Broad‑spectrum activity compatible with a range of existing antibiotics, enabling co‑formulation
- Demonstrated in vivo efficacy, e.g., boosting beta‑lactam effectiveness in chronic *S. aureus* infections from 30% to 85%
- Pipeline focused on priority pathogens such as *Staphylococcus aureus* and *Pseudomonas* spp. for device‑related and chronic wound applications